Omega-3 supplements with immunotherapy for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding omega-3 supplements to standard immunotherapy can help treat locally advanced stomach or gastroesophageal junction cancer. It aims to see if this combination improves outcomes for patients who have not yet received prior treatment for their current cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of locally advanced stage II or III stomach or gastroesophageal junction cancer.
- You have not had chemotherapy, radiation, or immunotherapy for this cancer before.
- Your overall health is good enough that you can care for yourself (ECOG score 0-2).
- You have adequate organ function based on routine blood tests.
- You are not pregnant, breastfeeding, or actively planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether giving immunotherapy after surgery can help prevent stomach cancer from coming back. It is for patients whose tumors show certain markers that suggest immunotherapy may work well.
This Phase 3 study tests how well immunotherapy given before surgery (neoadjuvant treatment) works for locally advanced stomach cancer. It aims to improve outcomes by tailoring treatment to different “immunotypes” (how the immune system and tumor behave).
Hear when a new Gastric Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.